2型糖尿病合并胃癌患者血清IGF-1、IGFBP-3的变化

目的:研究2型糖尿病（diabetes mellitus,DM）合并胃癌（gastric cancer,GC）患者血清胰岛素样生长因子-1（insulin-like growth factor-1,IGF-1）、胰岛素样生长因子结合蛋白-3(insulin-like growth factor binding protein-3,IGFBP-3)的变化。方法:选择2型DM患者30例（DM组）、2型DM合并GC患者48例（DM并GC组）为研究对象,ELISA 法测定血清IGF-1、 IGFBP-3水平;同时测定空腹血糖、空腹胰岛素、血脂水平。 结果:DM并GC组的IGF-1、IGF-1/IGFBP-3比值高于DM组（P<0.05）,IGFBP-3在两组之间无统计学差异（P>0.05）。IGF-1、IGF-1/IGFBP-3比值与空腹胰岛素水平呈正相关（r=0.598,0.626,P=0.000）,IGF-1/IGFBP-3比值是DM并GC患者淋巴结转移的危险因素（OR=2.142,P=0.001）。结论:IGF-1可能参与2型DM合并GC的发生及淋巴结转移。     

胃癌合并糖尿病患者血清IGF-1和IGFBP-3水平的变化及意义

目的探讨胃癌合并糖尿病患者血清胰岛素样生长因子-1(IGF-1)和胰岛素样生长因子结合蛋白-3(IGFBP-3)的变化及其临床意义。方法选取2017年3月至2018年12月间收治的100例胃癌患者,按照是否合并糖尿病进行分组,其中,合并糖尿病的55例患者纳入糖尿病合并胃癌组,未合并糖尿病的45例患者纳入单纯胃癌组,比较两组患者的血清IGF-1和IGFBP-3水平。结果糖尿病合并胃癌组IGF-1和IGFBP-3阳性率显著较单纯胃癌组高,差异均有统计学意义(均P <0. 05)。糖尿病合并胃癌组IGF-1和IGF-1/IGFBP-3水平显著高于单纯胃癌组,差异均有统计学意义(均P <0. 05),两组患者IGFBP-3组间比较,差异无统计学意义(P> 0. 05)。糖尿病合并胃癌组空腹血糖、餐后2h血糖和糖化血红蛋白显著高于单纯胃癌组,差异均有统计学意义(均P <0. 05)。IGF-1与IGFBP-3呈正相关,差异有统计学意义(P <0. 05)。将以上影响因素纳入多因素分析,结果表明,IGF-1、IGFBP-3、IGF-1/IGFBP-3、空腹血糖和糖化血红蛋白是糖尿病合并胃癌发生的危险因素,差异均有统计学意义(均P <0. 05),餐后2h血糖对糖尿病合并胃癌发生无明显影响,差异无统计学意义(P> 0. 05)。结论 IGF-1和IGFBP-3均参与糖尿病合并胃癌疾病发生过程,其值对于预测病情发展具有一定作用。     

IGFBP-2与结直肠癌的研究进展

胰岛素样生长因子结合蛋白2（IGFBP-2）是胰岛素样生长因子系统的一员,IGFBP-2在神经胶质瘤、结直肠癌、前列腺癌、卵巢癌、乳腺癌等多种恶性肿瘤细胞株、患者血清及其肿瘤组织中均有表达或表达水平升高。大量的临床实验及流行病学研究涉及了IGFBP-2与结直肠癌之间的关系,全文就目前IGFBP-2与结直肠癌的研究进展作一综述。     

胰岛素样生长因子及其结合蛋白在Ⅰ期非小细胞肺癌中的诊断价值

目的 探讨胰岛素样生长因子及其结合蛋白在Ⅰ期非小细胞肺癌中的诊断价值.方法 选择98例肺部病变患者为研究对象,根据病变程度分为良性病变组和Ⅰ期NSCLC组,采用ELISA方法测定所有患者血清中IGFBP-1 ～IGFBP-7、IGF-1和IGF-2的水平,比较2组间各水平的差异;进一步分析差异指标与Ⅰ期NSCLC临床参数的关系,并进行差异指标间的相关性分析.结果 良性病变组的IGFBP-3和IGFBP-5的水平高于Ⅰ期NSCLC患者的水平,IGF-1、IGF-2的水平低于Ⅰ期NSCLC组,差异均具有统计学意义(P＜0.05).而IGFBP-1、IGFBP-2、IGFBP-4、IGFBP-6、IGFBP-7、IGF-1/IGFBP-3、IGF-2/IGFBP-3在2组之间无统计学差异(P＞0.05).Ⅰ期NSCLC组中IGFBP-3、IGFBP-5、IGF-1、IGF-2的水平在肿瘤大小、淋巴结转移的有无、分化程度等临床参数分层之间具有统计学差异(P＜0.05).相关性的结果显示IG-FBP-3、IGFBP-5与IGF-1、IGF-2均呈明显负相关;IGF-1与IGF-2,IGFBP-3与IGFBP-5呈明显正相关.结论 胰岛素样生长因子(IGF-1和IGF-2)及胰岛素样生长因子结合蛋白(IGFBP-3和IGFBP-5)在Ⅰ期非小细胞肺癌中具有重要的诊断价值.     

IGF-1、IGFBP-3在非小细胞肺癌血清和组织中的表达及临床意义

目的 观察胰岛素样生长因子-1(IGF-1)、胰岛素样生长因子结合蛋白-3(IGFBP-3)在非小细胞肺癌(NSCLC)患者血清和肺癌组织中的表达及临床意义。方法 选择2019年1月至2020年1月本院收治的110例NSCLC患者作为观察组,另选择45例手术治疗的肺部良性病变患者作为对照组。收集患者临床资料,包括性别、年龄、肺癌部位、病理类型、肿瘤最大径、分化程度、TNM分期、有无淋巴结转移、局部侵犯程度等。于术前采用化学发光免疫分析法检测血清IGF-1、IGFBP-3水平;术后取观察组患者肿瘤组织、对照组患者远离病变部位的正常肺组织制作石蜡切片,采用免疫组化染色法染色观察组织IGF-1、IGFBP-3阳性表达;分析患者血清IGF-1、IGFBP-3水平和组织中IGF-1、IGFBP-3表达与NSCLC临床病理特征的关系;采用受试者特征工作(ROC)曲线分析血清IGF-1、IGFBP-3水平诊断NSCLC的价值。结果 观察组和对照组血清IGF-1水平分别为(162.74±41.39)μg/L和(130.28±26.46)μg/L;血清IGFBP-3水平分别为(1321.58±306.5...     

胰岛素、IGF及IGFBP与乳腺癌相关性研究

胰岛素抵抗、胰岛素样生长因子(IGF)和胰岛素样生长因子结合蛋白(IGFBP)-3的水平升高及IGFBP-1的水平降低可能与乳腺癌发生有关。合理的饮食、规律的体育锻炼，可降低肥胖女性胰岛素、IGF及IGFBP-3水平，预防乳腺癌发生。药物治疗可以改变胰岛素水平，降低IGF-Ⅰ生物效应，提高乳腺癌患者术后疗效。     

胰岛素、IGF及IGFBP与乳腺癌相关性研究

胰岛索抵抗、胰岛素样生长因子(IGF)和胰岛索样生长因子结合蛋白(IGFBP)-3的水平升高及IGFBP-1的水平降低可能与乳腺癌发生有关.合理的饮食、规律的体育锻炼,可降低肥胖女性胰岛素、IGF及IGFBP-3水平,预防乳腺癌发生.药物治疗可以改变胰岛素水平,降低IGF-Ⅰ生物效应,提高乳腺癌患者术后疗效.     

IGF-1、IGFBP-3在非小细胞肺癌组织中的表达及其临床意义

目的 探讨类胰岛素一号生长因子(IGF-1)、胰岛素样生长因子结合蛋白-3(IGFBP-3)在非小细胞肺癌(NSCLC)患者血清和肺癌组织中的表达及临床意义。方法 收集98例NSCLC纳入观察组,同时收集肺部良性病变40例纳入对照组。统计两组血清及肺癌组织中IGF-1、IGFBP-3表达。结果 观察组血清IGF-1水平高于对照组,IGFBP-3水平低于对照组,P<0.05。血清IGF-1、IGFBP-3水平与TNM分期、淋巴结转移、局部侵犯有关,P<0.05。观察组IGF-1阳性表达率显著高于对照组,IGFBP-3阳性表达率显著低于对照组,P<0.05。IGF-1、IGFBP-3阳性表达率与TNM分期、淋巴结转移、局部侵犯有关,P<0.05。血清IGF-1诊断NSCLC AUC为0.733,灵敏度55.5%,特异度91.2%,最佳截断值150.26μg/L;血清IGFBP-3诊断NSCLC AUC为0.799,灵敏度63.6%,特异度78.6%,最佳截断值1413.54μg/L。结论 NSCLC患者血清IGF-1、IGFBP-3主要与TNM分期、淋巴结转移及局部...     

2型糖尿病对鼻咽癌患者预后的影响

摘 要：［目的］ 观察2型糖尿病对鼻咽癌患者预后的影响。［方法］ 对2003年12月至2011年1月180例鼻咽癌患者资料进行回顾性分析。糖尿病组为2型糖尿病合并鼻咽癌病例共90例,对照组采用病例匹配方法,共纳入90例非糖尿病的鼻咽癌患者,应用Kaplan-Meier和Log-rank法计算和比较两组患者的5年总生存率、无复发生存率和无转移生存率。［结果］ 对照组和糖尿病组的5年总生存率分别是78.9%和68.9%（P＞0.05）;5年无转移生存率分别是89.7%和83.9%（P＞0.05）;5年无复发生存率分别为89.3%和78.2%（P＜0.05）。COX风险回归模型多因素分析结果显示,性别是局部晚期鼻咽癌总生存的独立预后因素（P=0.039）。［结论］ 2型糖尿病使鼻咽癌的复发率升高,值得进一步研究。     

血清VEGF、IGF-1/IGFBP-3在结直肠癌肝转移患者中的表达及其诊断价值

目的探讨血管内皮生长因子(VEGF)、血清胰岛素样生长因子1(IGF-1)和胰岛素样生长因子结合蛋白3(IGFBP-3)在结直肠癌肝转移(CRLM)患者中的表达情况及VEGF、IGF-1与IGFBP-3比值(IGF-1/IGFBP-3)诊断价值。方法回顾性分析2020年1月至2023年1月在宝鸡市中心医院初诊的41例CRLM患者(CRLM组)、70例结直肠癌(CRC)患者(CRC组)、85例结直肠息肉患者(结直肠息肉组)的临床资料, 选择同期体检健康者50例作为健康对照组。采用酶联免疫吸附试验测定VEGF的水平, 化学发光免疫分析法测定血清IGF-1及IGFBP-3的水平, 并对两组进行比较。采用受试者工作特征曲线以病理诊断结果为金标准, 评估上述指标单独及联合检测的效能。结果 CRLM组、CRC组、结直肠息肉组、健康对照组血清VEGF、IGF-1、IGFBP-3、IGF-1/IGFBP-3水平均逐级降低, 各组织间差异均有统计学意义(均P<0.05)。CRLM组VEGF、IGF-1、IGFBP-3、IGF-1/IGFBP-3水平均高于CRC组、结直肠息肉组和健康对照组, 差异均...     

肺癌患者血清PGE2水平及其对IL-2/sIL-2R的影响

目的 :探讨肺癌患者围手术期血清PGE2 水平的变化及其对IL 2 /sIL 2R的影响。方法 :采用放射免疫检测法 ( 12 5I RIA以及ELISA试剂盒 )分别检测 43例肺癌患者手术前、后的外周静脉血清PGE2 水平和IL 2 /sIL 2R ,术中抽取肿瘤回流静脉血用于检测PGE2 水平。结果 :肺癌患者外周静脉血存在较高的PGE2 ( 78 81± 3 2 15 )pg/mL ,与肿瘤回流静脉血中的PGE2 ( 13 1 0 7± 3 6 41)pg/mL呈显著相关 ,r =-0 3 15 ,P <0 0 1,术后其PGE2 显著下降 ;手术前后其IL 2 /sIL 2R处于相对较低水平 ,IL 2与PGE2 呈相关关系 ,而与sIL 2R无明显相关。术后IL 2有所上升 ( 15 3 83± 5 3 3 9)pg/mL ,但仍低于正常对照组 ( 2 3 0 2 9± 5 3 3 9)pg/mL ,P <0 0 5。结论 :肺癌患者存在着高水平的PGE2 ,是由肺部肿瘤引起的 ,对IL 2有一定的抑制作用。     

Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin

Purpose  The present study analyzed the polymorphisms of apoptosis-related genes and their impact on the response to chemotherapy and survival of patients with colorectal cancer. Patients and methods  A total of 76 patients with recurrent or metastatic colorectal cancer treated with capecitabine and oxaliplatin (XELOX) combination chemotherapy were enrolled in the present study. The single nucleotide polymorphisms of 15 apoptosis-related genes (TP53, BCL2L, TNFRSF10B, AKT1, PTGS2/COX2, BID, RIPK1, FAS, FASL, caspase 3, and caspase 6-10) were determined using a PCR-RFLP assay. Results  No significant association between the polymorphisms and the response was found for any of the genes analyzed. However, the T/T genotype of PTGS2 8473T>C (rs5275) was significantly correlated with a better progression-free survival (PFS) and overall survival (OS) when compared to the combined T/C and C/C genotype (Hazard ratio [HR] = 0.47; P value = 0.046 and HR = 0.16; P = 0.013, respectively) in a multivariate analysis adjusted for age, sex, performance status, disease status and curative resection. No association was noted between the other polymorphisms and survival. Conclusion  The PTGS2 8473T>C polymorphism was found to be correlated with PFS and OS in patients with advanced colorectal cancer treated with XELOX chemotherapy.     

Thyroiditis after treatment with interleukin-2 and interferon alpha-2a

Serial thyroid functions studies were carried out in patients with melanoma and renal cell carcinoma treated with interleukin-2 (3 MU m-2 by continuous infusion days 1-4) and interferon alpha-2a (6 MU m-2 subcutaneously on days 1 and 4), both given on alternate weeks. The results on eight patients who completed at least three cycles of treatment are described. Four patients developed thyroid dysfunction with a hyperthyroid phase of 2 weeks followed by a hypothyroid phase ranging from 12 to 24 weeks. Two patients became clinically symptomatic and required treatment. Fine-needle aspirates of the thyroid were obtained in three patients with thyroid dysfunction. The cytology revealed a mixed cellular infiltrate with lymphocytes and histiocytes, and immunocytochemical staining showed strong HLA-DR expression of all thyrocytes, both suggestive of an autoimmune thyroiditis. One patient with thyroiditis developed anti-thyroglobulin antibodies, the serology of all other patients was normal. Patients with thyroid dysfunction tended to have higher in vivo stimulated lytic activity of peripheral mononuclear blood cells and had significantly higher levels of CD16 positive blood cells as compared to euthyroid patients. The possibility of autoimmune thyroiditis should be anticipated in future trails combining interleukin-2 and interferon alpha-2a.     

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort

BackgroundHER2 mutations have been identified as oncogenic drivers in lung cancers and are found in 1–2% of lung adenocarcinomas. There is, to date, no standard of care for these patients. We thus aim to study the therapeutic outcomes of patients harboring HER2 mutations and establish the efficacy of various drug regimens.Patients and methodsThis retrospective cohort study in European centers assessed patients with advanced non-small-cell lung cancer (NSCLC), a known HER2 exon-20 insertion, treated with chemotherapy and/or HER2-targeted drugs.ResultsWe identified 101 eligible patients from 38 centers: median age 61 years (range: 30–87), 62.4% women, 60.4% never-smokers. All tumors were adenocarcinomas. Concomitant EGFR mutations, ALK translocations, and ROS translocations were observed in 5, 1, and 1 patients, respectively. The median number of treatment lines was 3 (range: 1–11). The median overall survival was 24 months. Overall response rate (ORR) and the median progression-free survival (PFS) with conventional chemotherapy (excluding targeted therapies) were 43.5% and 6 months in first-line (n = 93), and 10% and 4.3 months in second-line (n = 52) therapies. Sixty-five patients received HER2-targeted therapies: trastuzumab = 57, neratinib = 14, afatinib = 9, lapatinib = 5, T-DM1 = 1. ORR was 50.9% and PFS was 4.8 months with trastuzumab or T-DM1.ConclusionThis series shows the chemosensitivity of HER2-driven NSCLC, and the potential interest of HER2-targeted agents. Our results should help to define the best therapeutic strategy for these patients and to orient future clinical trials.